GLP-1 and Fertility: Safety Evidence for Pregnancy Planning

GLP-1 receptor agonists such as Ozempic (semaglutide) and Mounjaro (tirzepatide) are not classified as contraindicated in pregnancy by FDA guidance, though clinical experience remains limited. Current evidence suggests these medications do not increase major birth defect risk in animal models, but robust human pregnancy data is sparse.

For individuals planning conception while managing weight or type 2 diabetes, the decision to continue, pause, or adjust GLP-1 therapy involves multiple factors: metabolic health status, fertility timelines, and individual clinical context. PlexusDx emphasizes precision wellness by helping patients understand their unique metabolic and genetic predispositions before initiating or modifying treatment conversations with their healthcare provider.

What Does Current Evidence Show About GLP-1 Use During Pregnancy?

Semaglutide and tirzepatide have demonstrated reproductive safety in animal toxicology studies up to high doses, with no teratogenic signals reported. However, human pregnancy exposure data remains limited because these medications are relatively new and pregnancy represents a vulnerable population excluded from initial clinical trials.

A 2023 Swedish registry analysis of approximately 900 semaglutide-exposed pregnancies found no increased risk of congenital malformations compared to the general population. Despite this reassuring preliminary signal, professional organizations including the American College of Obstetricians and Gynecologists recommend individualized counseling and informed decision-making rather than blanket endorsement or prohibition.

Metabolic Context and Fertility: Key Factors in Your Decision

Weight management and metabolic health directly influence fertility, ovulation regularity, and pregnancy outcomes. GLP-1 medications improve insulin sensitivity and weight loss, which may enhance reproductive function in individuals with obesity or metabolic dysfunction. However, rapid weight loss during early pregnancy may complicate nutritional adequacy and fetal development.

The following framework helps clarify the interplay between GLP-1 therapy, metabolic goals, and fertility planning. Consider your specific clinical situation—such as diabetes status, BMI baseline, and conception timeline—before making adjustments.

Gastrointestinal Effects and Nutritional Adequacy During Conception and Early Pregnancy

GLP-1 receptor agonists reduce appetite and slow gastric emptying, which may decrease oral intake and nutrient absorption. During the periconception period and first trimester, adequate micronutrient status—including folate, iron, vitamin B12, and iodine—is critical for fetal neural development and preventing complications.

If continuing GLP-1 during pregnancy or attempting conception, coordinate with your provider or registered dietitian to ensure sufficient caloric and micronutrient intake. Reduced appetite must not compromise the nutritional reserves required for a healthy pregnancy, particularly if gastrointestinal side effects persist.

Making an Informed Decision: Safety Considerations and Provider Guidance

The decision to use, pause, or adjust GLP-1 medications during fertility planning is not standardized and depends on your individual diagnosis, metabolic goals, and reproductive timeline. No national guideline currently mandates stopping GLP-1 before conception, but many providers recommend discussing the transition plan at least 3–6 months before attempting pregnancy.

Work closely with both your reproductive endocrinologist or OB-GYN and your weight management or diabetes provider to create a coordinated plan. Shared decision-making, informed consent, and documented conversations about risks, benefits, and alternatives are essential components of responsible reproductive care.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test reveals predispositions in key peptide pathways—including GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313)—that may help provide context for how your body metabolically responds to GLP-1 medications. Understanding these genetic predispositions can support a more informed conversation with your provider about the likelihood of metabolic benefit and individual medication tolerance, which may influence fertility and conception planning decisions.

Genetic variants in the GLP-1 receptor and appetite-regulation genes do not predict exact medication response or pregnancy outcome, but they may inform your provider's risk-benefit assessment. For example, certain FTO variants are associated with higher baseline obesity risk, which may increase the clinical rationale for sustained metabolic support during conception planning. These insights should be interpreted with a qualified healthcare provider who understands both your genetic context and reproductive goals.

Sharing your Precision Peptide Genetic Test results with your obstetrician, reproductive endocrinologist, and prescribing provider can facilitate more personalized counseling about GLP-1 use, weight management strategies, and metabolic health during the periconception period. This data may also inform discussions about alternative interventions or medication adjustments that align with your fertility and pregnancy planning timeline.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $229-$509/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Related Reading

• Can A Dna Test Reveal If I Will Benefit From Glp 1 Medications
• Glp 1 Medications
• Do Genetic Tests Help Identify People Who Will Benefit From Glp 1 Medications
• Can You Get Your Glp 1 Tested